Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (41-50 of 198) with videos related to

Pageof 20
Sort By:
Immunotherapy|June 30, 2021
Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumabAntonello Veccia, Vincenzo Sforza, Emanuela Vattemi, et al.
Expert Opinion on Drug Safety|March 31, 2010
Vinorelbine for non-small cell lung cancerMaria Carmela Piccirillo, Gennaro Daniele, Massimo Di Maio, et al.
Expert Opinion on Investigational Drugs|August 5, 2014
Vandetanib as a potential treatment for breast cancerAntonella De Luca, Amelia D'Alessio, Monica Rosaria Maiello, et al.
Cancers|April 3, 2021
Novel Cytotoxic Chemotherapies in Small Cell Lung CarcinomaDiego Cortinovis, Paolo Bidoli, Stefania Canova, et al.
Plos One|July 26, 2019
Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperationRosa Camerlingo, Roberta Miceli, Laura Marra, et al.
Expert Opinion on Biological Therapy|March 21, 2017
Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?Federica Zito Marino, Paolo Antonio Ascierto, Giulio Rossi, et al.
Cancers|December 22, 2020
Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and PitfallsRiziero Esposito Abate, Daniela Frezzetti, Monica Rosaria Maiello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2013
Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutationsAlessandro Morabito, Raffaele Costanzo, Anna Maria Rachiglio, et al.
Cancer Cytopathology|February 15, 2017
Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: Cytological smears versus cell blocksFederica Zito Marino, Giulio Rossi, Matteo Brunelli, et al.
Current Pharmaceutical Design|November 7, 2013
Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better…Massimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, et al.
Pageof 20

Showing results (41-50 of 198) with videos related to

Sort By:
Pageof 20
Immunotherapy|June 30, 2021
Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumabAntonello Veccia, Vincenzo Sforza, Emanuela Vattemi, et al.
Expert Opinion on Drug Safety|March 31, 2010
Vinorelbine for non-small cell lung cancerMaria Carmela Piccirillo, Gennaro Daniele, Massimo Di Maio, et al.
Expert Opinion on Investigational Drugs|August 5, 2014
Vandetanib as a potential treatment for breast cancerAntonella De Luca, Amelia D'Alessio, Monica Rosaria Maiello, et al.
Cancers|April 3, 2021
Novel Cytotoxic Chemotherapies in Small Cell Lung CarcinomaDiego Cortinovis, Paolo Bidoli, Stefania Canova, et al.
Plos One|July 26, 2019
Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperationRosa Camerlingo, Roberta Miceli, Laura Marra, et al.
Expert Opinion on Biological Therapy|March 21, 2017
Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?Federica Zito Marino, Paolo Antonio Ascierto, Giulio Rossi, et al.
Cancers|December 22, 2020
Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and PitfallsRiziero Esposito Abate, Daniela Frezzetti, Monica Rosaria Maiello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2013
Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutationsAlessandro Morabito, Raffaele Costanzo, Anna Maria Rachiglio, et al.
Cancer Cytopathology|February 15, 2017
Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: Cytological smears versus cell blocksFederica Zito Marino, Giulio Rossi, Matteo Brunelli, et al.
Current Pharmaceutical Design|November 7, 2013
Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better…Massimo Di Maio, Alessandro Morabito, Maria Carmela Piccirillo, et al.
Pageof 20